NL-OMON19994已完成不适用
Switching to aflibercept in patients with neovascular age-related macular degeneration not responding to anti-VEGF treatment: a pilot study
Prof. Dr. C.B. HoyngRadboud University Nijmegen Medical Centre, Ophthalmology Department0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with inadequate response to prior anti-VEGF treatment defined as a persistent central retinal thickness (CRT) of ¡Ý300 ¦Ìm combined with a response of no greater than a reduction of 50 ¦Ìm in CRT on OCT after each previous intravitreal anti-VEGF treatment.
- •- Patients will have received at least 6 anti-VEGF injections within 1 year.
排除标准
- •- Signs of subretinal fibrosis, scarring or geographic atrophy on OCT or FA, involving the center of the macula.
- •- Pigment epithelial detachment with a height of ¡Ý150¦Ìm.
研究者
相似试验
进行中（未招募）
1 期
Switching to aflibercept in patients with wet AMD not responding to anti-VEGF treatment.eovascular Age-related macular degenerationEUCTR2013-001208-12-NLRadboud University Nijmegen Medical Centre20
已完成
4 期
Switching to aflibercept in patients with neovascular AMD not responding to anti-VEGF treatment.10047060macular degenerationage-related macular degenerationNL-OMON38763niversitair Medisch Centrum Sint Radboud20
已完成
不适用
Study of efficacy of aflibercept in neovascular age-related macular degeneration (wAMD) with refractory of ranibizumabAge-related macular degenerationJPRN-UMIN000010578agoya City University Graduate School of Medical Sciences50
已完成
不适用
Study of efficacy of aflibercept in neovascular age-related macular degeneration (wAMD) with non-responder of ranibizumabAge-related macular degenerationJPRN-UMIN000010577agoya City University Graduate School of Medical Sciences50
已完成
4 期
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous TreatmentAge-related Macular Degeneration (ARMD)NCT06683950Kim's Eye Hospital35